About Taste receptor type 2 member 50
Taste receptor type 2 member 50 (TAS2R50) is a protein
from Homo sapiens identified by UniProt accession
P59544, 299 residues long.
MolForge cross-references it against 0 known binders and
14 disease associations.
Target properties
| Protein name | Taste receptor type 2 member 50 |
|---|
| UniProt accession | P59544 |
|---|
| Gene | TAS2R50 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 299 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (14)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.36
- lung adenocarcinoma · score 0.18
- ovarian cancer · score 0.18
- neuroblastoma · score 0.11
- sensory perception of bitter taste · score 0.10
- coffee consumption measurement · score 0.07
- tea consumption measurement · score 0.06
- actinic keratosis · score 0.04
- coffee consumption · score 0.03
- breast carcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P59544-F1 | alphafold | PREDICTED | 85.06 | — |
Amino-acid sequence (299 residues)
MITFLYIFFS ILIMVLFVLG NFANGFIALV NFIDWVKRKK ISSADQILTA LAVSRIGLLW ALLLNWYLTV LNPAFYSVEL RITSYNAWVV TNHFSMWLAA NLSIFYLLKI ANFSNLLFLH LKRRVRSVIL VILLGTLIFL VCHLLVANMD ESMWAEEYEG NMTGKMKLRN TVHLSYLTVT TLWSFIPFTL SLISFLMLIC SLCKHLKKMQ LHGEGSQDLS TKVHIKALQT LISFLLLCAI FFLFLIVSVW SPRRLRNDPV VMVSKAVGNI YLAFDSFILI WRTKKLKHTF LLILCQIRC
Explore Taste receptor type 2 member 50 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets